The AAPS Journal

, Volume 14, Issue 2, pp 262–281

Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation

Authors

  • Peng Zou
    • Department of Pharmaceutical Sciences, College of PharmacyUniversity of Michigan
  • Yanke Yu
    • Department of Pharmaceutical Sciences, College of PharmacyUniversity of Michigan
  • Nan Zheng
    • Department of Pharmaceutical Sciences, College of PharmacyUniversity of Michigan
  • Yongsheng Yang
    • Office of Testing and Research, Center for Drug Evaluation and ResearchFood and Drug Administration
  • Hayley J. Paholak
    • Department of Pharmaceutical Sciences, College of PharmacyUniversity of Michigan
    • Office of Generic Drugs, Center for Drug Evaluation and ResearchFood and Drug Administration
    • Department of Pharmaceutical Sciences, College of PharmacyUniversity of Michigan
Review Article

DOI: 10.1208/s12248-012-9332-y

Cite this article as:
Zou, P., Yu, Y., Zheng, N. et al. AAPS J (2012) 14: 262. doi:10.1208/s12248-012-9332-y

Abstract

Quantitative estimations of first-in-human (FIH) doses are critical for phase I clinical trials in drug development. Human pharmacokinetic (PK) prediction methods have been developed to project the human clearance (CL) and bioavailability with reasonable accuracy, which facilitates estimation of a safe yet efficacious FIH dose. However, the FIH dose estimation is still very challenging and complex. The aim of this article is to review the common approaches for FIH dose estimation with an emphasis on PK-guided estimation. We discuss 5 methods for FIH dose estimation, 17 approaches for the prediction of human CL, 6 methods for the prediction of bioavailability, and 3 tools for the prediction of PK profiles. This review may serve as a practical protocol for PK- or pharmacokinetic/pharmacodynamic-guided estimation of the FIH dose.

KEY WORDS

allometric scalingFIH dosein vitro–in vivo correlationspharmacokineticsprediction

Copyright information

© American Association of Pharmaceutical Scientists 2012